RE:Current avenuesThe outcomes , Onc future?
partership ( only) , is a fluid concept.
Many buyouts, began with a partership, or % ownership etc.
regardless of who is on what board, the decisions will be based on business opportunities for the aquiring company.
I know from history, management indicated a buyout would be minimum a $billion.
That was a long time ago.
Taking a very wide lense view of the situation.....
Oncolyitics biotech was incorporated with a mission statement. That being to get Pelareorep to market as a cancer therapy.
To the beet of my knowledge thst has not changed.
The A.N. Deal, was an opportunity to do that.
So? The science AKA FDA approvals, CGAR trial & others are required to get to the end game.....getting Pela to market.
Another side note, there was strong expectations of a B.D. Deal. Long before the Aware-1, bracelet, & Gobblet.
That deal died, because the aquiring company wanted complete control over Pela use. Including killing the product.
Being in conflict with the company mission, that deal was not completed.....that was years ago & just before the A.N. Deal.
Is the A.N. Deal good or bad? Even that fits the description " proof will be in the pudding".
Since Onc maintains control over the Pela use , even though the A.N. Deal. The other details still must be set up.
Assuming the FDA discussions land enough detail to move the MBc to phase 3, then A.N. Can start their version of the phase 3.
That will trigger, milestone payments.Certainly a welcome cash infusion.
Myself? I'd prefer a direct total buyout. However, Roche and/ or Pfizer might get into a licensing deal, similar to A.N.
Helping to fund phase 3, without having to risk the whole $$$.
Decisions like that, & why the delay?
The N.R. Regarding FDA meeting is very important. as well as the very long awaited O.S. Numbers from Bracelet.
Assuming there are negotiations. Onc sees a huge potential, as / company web site. Now two & leanin* towards a possible third registration trial.
On the other side of the table, larger pharma is saying, " we need proof".
The FDA outcome will be a very important, level of that proof.
Who ever would buy Onc outright , would also own the licensing agreement with A.N.
That value alone will increase substantially, once MBc phase 3 details are completed.
Again, the goal is to get Pela to market.
from the very beginning, it was stated they would sell or license that opportunity.
Assuming the published info is reasonably accurate, there will be answers before the end of this quarter.
it has been an extreme ly long , frustrating process. Many changes along the way.
saying that, the FDA, meeting request , Roche Gobblet additions & pending bracelet O.S. Numbers...
indicate , & I have said too many times. Do or die soon.
indications leaning towards do....